共 50 条
Mast Cells as Drivers of Disease and Therapeutic Targets
被引:98
|作者:
Siebenhaar, Frank
[1
]
Redegeld, Frank A.
[2
]
Bischoff, Stephan C.
[3
]
Gibbs, Bernhard F.
[4
,5
]
Maurer, Marcus
[1
]
机构:
[1] Charite, Dept Dermatol & Allergy, Berlin, Germany
[2] Univ Utrecht, Div Pharmacol, Dept Pharmaceut Sci, Fac Sci, Utrecht, Netherlands
[3] Univ Hohenheim, Dept Nutr Med & Immunol, Stuttgart, Germany
[4] Univ Kent, Medway Sch Pharm, Canterbury, Kent, England
[5] Carl von Ossietzky Univ Oldenburg, Dept Dermatol & Allergol, Oldenburg, Germany
关键词:
RECEPTOR ANTAGONISTS;
SYSTEMIC MASTOCYTOSIS;
SKIN INFLAMMATION;
CATHEPSIN-G;
ALLERGEN;
DEGRANULATION;
INHIBITION;
OMALIZUMAB;
MEDIATORS;
EFFICACY;
D O I:
10.1016/j.it.2017.10.005
中图分类号:
R392 [医学免疫学];
Q939.91 [免疫学];
学科分类号:
100102 ;
摘要:
Mast cells (MCs) contribute to the pathogenesis of a multitude of diseases that include MC-driven disorders such as urticaria, type I allergies, and mastocytosis as well as autoimmune and other inflammatory disorders and malignant tumors. Here, we review and discuss the results of studies that identified and characterized how MCs contribute to disease and, importantly, what strategies may be used to target MCs and MC effects therapeutically. Specifically, we discuss the most common approaches for investigating the role and relevance of MCs in various diseases. We also review current therapeutic approaches aimed at modulating MC numbers, inhibiting MCs and/or preventing MC activation, modulating MC signal transduction and protection from the effects of MC mediators.
引用
收藏
页码:151 / 162
页数:12
相关论文